25 results on '"Massacesi, A"'
Search Results
2. Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)
3. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
4. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
5. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
6. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
7. A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4)
8. MO-08.1 - A PROCEDURE FOR ANALYSIS OF MS TISSUE DAMAGE THROUGH QUANTITATIVE DTI
9. Present and future breast cancer management—bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry
10. Alice in wonderland syndrome “through the looking-glass” in a rare presentation of non-convulsive status epilepticus in cerebral venous sinus thrombosis and COVID-19
11. Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoring
12. High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer
13. Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD)
14. A synthetic glycopeptide of human myelin oligodendrocyte glycoprotein to detect antibody responses in multiple sclerosis and other neurological diseases
15. 193 Phase I Safety Experience with the Oral Pan-class I PI3K Inhibitor BKM120 in Patients with Metastatic Breast Cancer (mBC)
16. 436 Trastuzumab- (H) and everolimus- (RAD001) containing regimens are safe and active when reintroduced in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) pre-treated with lapatinib
17. 5021 Everolimus (RAD001) in combination with weekly paclitaxel and trastuzumab in patients (pts) with HER-2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab: a multicenter phase I clinical trial
18. 5004 Multicenter phase I clinical trial of daily and weekly everolimus (RAD001) in combination with vinorelbine and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab
19. Gemcitabine-cisplatin (GP) vs gemcitabine-carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): a multicenter phase II randomized trial
20. Spectroscopic and biological studies on palladium(II) complexes with N-ethyl and N-propylimidazole
21. Spectroscopic studies on some bivalent metallic complexes formed with three different bidentate polyamines
22. Inhibitorial effect of the Cu(II) and Ni(II) complexes with polyamines and imidazole derivatives on the Ca, Mg-dependent ATP-ase substrate
23. Inhibitory activity of bivalent transition-metal complexes with diamines toward a diamine oxidase
24. EPR studies on copper(II) in four divalent diamagnetic metallic complexes of 3-amino,5-methylisoxazole
25. Copper(II) complexes of 4-chloro,3-methyl,5-phenylisoxazole
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.